GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Forward Dividend Yield %

BioPlus Acquisition (BioPlus Acquisition) Forward Dividend Yield % : 0.00% (As of May. 10, 2024)


View and export this data going back to 2022. Start your Free Trial

What is BioPlus Acquisition Forward Dividend Yield %?

As of today (2024-05-10), the Forward Annual Dividend Yield of BioPlus Acquisition is 0.00%.

As of today (2024-05-10), the Trailing Annual Dividend Yield of BioPlus Acquisition is 0.00%.

BIOS's Forward Dividend Yield % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 3.585
* Ranked among companies with meaningful Forward Dividend Yield % only.

BioPlus Acquisition's Dividends per Share for the three months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of BioPlus Acquisition's Forward Dividend Yield %

For the Shell Companies subindustry, BioPlus Acquisition's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPlus Acquisition's Forward Dividend Yield % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where BioPlus Acquisition's Forward Dividend Yield % falls into.



BioPlus Acquisition Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


BioPlus Acquisition  (NAS:BIOS) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


BioPlus Acquisition Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPlus Acquisition (BioPlus Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000